Johnson & Johnson posted strong second-quarter 2025 results, driven by 22.3% growth in cardiology and 13% growth across its med-tech segments. Innovative medicines grew nearly 5%, offsetting a 43% decline in Stelara sales due to biosimilar competition. Oncology treatments, particularly Darzalex, showed substantial revenue gains. The company raised its operational growth forecast and expects adjusted earnings per share to rise. The results underscore resilience amid patent cliffs and ongoing tariff impacts.